Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 3/2016

01-03-2016 | Literatur kommentiert

Langzeitergebnisse zweier verschiedener Behandlungskonzepte mit HDR-Brachytherapie-Boost bei Prostatakarzinomen mit intermediärem Risiko

Authors: Dr. med. Nina Seibold, Prof. Dr. med., Dr. med. univ.(H), C.Sc.(H) György Kovács

Published in: Strahlentherapie und Onkologie | Issue 3/2016

Login to get access

Auszug

Bei der dosiseskalierten Bestrahlung lokal begrenzter Prostatakarzinome ist der High-Dose-Rate-(HDR-)Brachytherapie-Boost inzwischen Standard [1]. Publizierte Daten weisen auf bessere Ergebnisse hin, wenn der HDR-Boost zeitgleich mit der perkutanen Bestrahlung (EBRT) appliziert wird [2, 3]. Jedoch werden die optimale Dosis und die Fraktionierung in der Literatur noch diskutiert [1, 4‐6]. Die hier kommentierte Arbeit vergleicht zwei verschiedene Behandlungskonzepte von zwei bisher veröffentlichten Phase-II-Studien. …
Literature
1.
2.
Pieters BR, Van de Kamer JB, Van Herten YRJ et al (2008) Comparison of biologicaly equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol 88:46–52CrossRefPubMed
3.
Hoskin PJ, Rojas AM, Bownes PJ et al (2012) Randomized trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localized prostate cancer. Radiother Oncol 103:217–222CrossRefPubMed
4.
Yamada Y, Rogers I, Demanes DJ et al (2012) American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 11:20–32CrossRefPubMed
5.
Morton G, Loblaw A, Cheung P et al (2011) Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? Radiother Oncol 100:463–467CrossRefPubMed
6.
Morton GG, Loblaw A, Sankreacha R et al (2010) Single-fraction high dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life. Int J Radiat Oncol Biol Phys 77:811–817CrossRefPubMed
7.
Deutsch I, Zelefsky MJ, Zhiang Z et al (2010) Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination of HDR brachytherapy and IMRT. Brachytherapy 9:313–318CrossRefPubMed
8.
Pritz J, Forster KM, Saini AS et al (2012) Providing a fast conversion of total dose to biological effective dose (BED) for hybrid seed brachytherapy. J Appl Clin Med Phys 13:24–32
9.
Sanfilippo NJ, Cooper BT (2014) Hypofractionated radiation therapy for prostate cancer: biologic and technical considerations. Am J Clin Exp Urol 2:286–293PubMedCentralPubMed
10.
Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43:1095–1101CrossRefPubMed
Metadata
Title
Langzeitergebnisse zweier verschiedener Behandlungskonzepte mit HDR-Brachytherapie-Boost bei Prostatakarzinomen mit intermediärem Risiko
Authors
Dr. med. Nina Seibold
Prof. Dr. med., Dr. med. univ.(H), C.Sc.(H) György Kovács
Publication date
01-03-2016
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 3/2016
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-015-0937-9

Other articles of this Issue 3/2016

Strahlentherapie und Onkologie 3/2016 Go to the issue

Literatur kommentiert

Kardiale Toxizität von Trastuzumab in der adjuvanten Therapie von Mammakarzinompatientinnen

Original Article

Automatically gated image-guided breath-hold IMRT is a fast, precise, and dosimetrically robust treatment for lung cancer patients

Original Article

Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients

Original Article

Stereotactic intracavitary brachytherapy with P-32 for cystic craniopharyngiomas in children

Original Article

Temporal changes in tumor oxygenation and perfusion upon normo- and hyperbaric inspiratory hyperoxia

Original Article

Primary glioblastoma multiforme tumors and recurrence